| 2026-08-12 | Press release | Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million |
| 2026-08-05 | Press release | Royalty Pharma reports second quarter 2026 results |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-05 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-03 | Press release | Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives |
| 2026-07-22 | Press release | Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune |
| 2026-07-17 | Press release | Royalty Pharma declares third quarter 2026 dividend |
| 2026-07-15 | Press release | Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 |
| 2026-06-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-28 | Deck | Corporate presentation |
| 2026-05-28 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-06 | Press release | Royalty Pharma reports first quarter 2026 results |
| 2026-05-06 | Deck | Investor presentation · Q1 2026 · May 2026 |
| 2026-05-06 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-21 | Press release | Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation |
| 2026-04-17 | Press release | Royalty Pharma Declares Second Quarter 2026 Dividend |
| 2026-04-15 | Press release | Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-14 | ESG report | 2025 Corporate Responsibility Report |
| 2026-04-13 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-10 | Proxy | Definitive proxy statement |
| 2026-03-31 | Press release | Pre-quarterly results communication · Q1 2026 |
| 2026-03-30 | Press release | Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases |
| 2026-03-23 | Press release | Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence |
| 2026-03-17 | Press release | Royalty Pharma Announces Expansion of Leadership Team |
| 2026-03-02 | Press release | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma’s Global Platform |
| 2026-03-02 | Press release | Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing |
| 2026-02-26 | Press release | Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference |
| 2026-02-15 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-12 | Deck | Full Year and Q4 2025 Financial Results |
| 2026-02-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-11 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-20 | Press release | Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 |
| 2026-01-13 | Deck | J.P. Morgan Healthcare Conference Presentation |
| 2026-01-12 | Press release | Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-09 | Press release | Royalty Pharma Announces Dividend Increase |
| 2025-12-29 | Press release | Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones |
| 2025-12-22 | 8-K | Form 8-K, Item 7.01 |